@PFDestion::ODMA/MANAGE;383956;1
AJC:V 1:1cc
03/2405

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Debra M. Eckert, David C. Chan, Vladimir Malashkevich, Peter A. Carr and Peter S. Kim

Application No.: 09/746,742 Group Art Unit: 1627

Filed: December 21, 2000 Examiner: Celsa, B.M.

Confirmation No.: 8580

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Assistant Commissioner for Patents, P.O. Box 2327, Arlington, VA

22202

on 3.24.03

Date Signature

Typed or printed name of person signing certificate

Inhibitors of HIV Membrane Fusion

## 2<sup>nd</sup> SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents P.O. Box 2327 Arlington, VA 22202

Title:

Sir: This Information Disclosure Statement is submitted: under 37 CFR 1.129(a), or (First/Second submission after Final Rejection) under 37 CFR 1.97(b), or [X](Within any one of the following time periods: three months of filing national application (other than a CPA) or date of entry of the national stage in an international application; or before the mailing date of a first office action on the merits in a non-provisional application, including a CPA, or a Request for Continued Examination). under 37 CFR 1.97(c) together with either: [] a Statement under 37 CFR 1.97(e), as checked below, or a \$180.00 fee under 37 CFR 1.17(p), or [ ] (After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first) under 37 CFR 1.97(d) together with: a Statement under 37 CFR 1.97(e), as checked below, and a \$180.00 fee under 37 CFR 1.17(p), or (Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee)

under 37 CFR 1.97(i):
Applicant requests that the IDS and cited reference(s) be placed in the application filewrapper.

(Filed after payment of issue fee)

Statem	ent I Inde	or 37 CFR 1.97(e)			
	Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or				
[ ]	No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.				
Stater		er 37 CFR 1.704(d) (Patent Term Adjustment) Applies to original applications (other than design) filed on or after May 29, 200	0		
[ ] Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.					
F373	Englos	ed herewith is form PTO-1449:			
ĮΧJ					
	[X]	Copies of the cited references are enclosed (AY9-AZ9 and AR10-AW10).			
	[ ]	Copies of cited references are enclosed except those entered in prior application, U.S. Application No. [ ], to which priority under 35 U.S.C. 120 is claimed. [The earlier application contains copies of the cited references.]	r		
	[ ]	The listed references were cited in the enclosed International Search Report in a counterpart foreign application.			
	[ ]	The "concise explanation" requirement (non-English references) for reference(s) [ under 37 CFR 1.98(a)(3) is satisfied by:	]		
		[ ] the explanation provided on the attached sheet.			
		the explanation provided in the Specification.			
		submission of the enclosed International Search Report.			
		[ ] submission of the enclosed English-language version of a foreign Search Repor and/or foreign Office Action.	t		
		[ ] the enclosed English language abstract.			

[ ]	Appli	Applicant requests that the following non-published pending applications be considered:				
Examiner's Initials						
		U.S. Patent Application No. [	], by [inventor(s)], filed [	], Docket No.: [ ]		
		U.S. Patent Application No. [	], by [inventor(s)], filed [	], Docket No.: [ ]		
<del>-</del>		U.S. Patent Application No. [	], by [inventor(s)], filed [	], Docket No.: [ ]		
		Examiner	Date	_		
	[ ]	A copy of each above-cited app	plication, including the curre	ent claims, is enclosed.		
	[]	A copy of each above-cited appethose entered in prior application 35 U.S.C. 120 is claimed.	olication, including the curre on, U.S. Application No. [	ent claims, is enclosed, except ], to which priority under		
The E	xamino nces w	er is requested to return a copy of ere considered with the next office	the above list of pending ap the communication.	oplications indicating which		
It is re	queste	ed that the information disclosed h	nerein be made of record in	this application.		
Metho	d of p	ayment:				
[ ]	A ch	eck for the fee noted above is encompanying Reply. A copy of this s	losed, or the fee has been in Statement is enclosed.	cluded in the check with the		
[]		use charge Deposit Account 08-0380 in the amount of \$[ ]. A copy of this Statement is osed.				
[X]	Please charge any deficiency in fees and credit any overpayment to Deposit Account 08-038					
		1	Respectfully submitted,			
		1	HAMILTON, BROOK, SM	ITH & REYNOLDS, P.C.		
			Anne J. Collins Registration No.: 40,564 Telephone: (978) 341-003 Facsimile: (978) 341-013			

Concord, MA 01742-9133
Dated: War Ch 2 4, 2023

MINED	DATE CONSIDERED	
EXAMINER		

Virus Type 1 Transmembrane Protein gp41," J. Virol. 72(12):9676-9682 (1998).

AW10

Weng, Y., et al., "Mutational Analysis of Residues in the Coiled-Coil Domain of Human Immunodeficiency